I don't recall any ASX announcement from the company regarding the publication of this important trial, with the Recell kits donated by the Fiona Wood Foundation
"Trial recruitment was terminated early on advice from the DSMB. The initial catalyst for requesting a DSMB review was concern of an excess of SAE (serious adverse events) and AE (adverse events) in the intervention group, slow recruitment rates and lack of an ongoing funding stream."
Essentially the frequency of adverse events in the intervention group prompted the DSMB to request an interim analysis and a futility analysis showed Recell was no better than standard of care and it was futile to continue the trial.
Recell was an expensive waste of time in treating diabetic foot ulcers.
Although the trial is listed on the company website as a reference, when I attempted to load it it got stuck.
I don't think they ever announced it or mentioned it in the company reports.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)